摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2(S)-azido-3-ethylpentanoic acid | 544437-62-9

中文名称
——
中文别名
——
英文名称
2(S)-azido-3-ethylpentanoic acid
英文别名
(2S)-2-azido-3-ethylpentanoic acid
2(S)-azido-3-ethylpentanoic acid化学式
CAS
544437-62-9
化学式
C7H13N3O2
mdl
——
分子量
171.199
InChiKey
BLZHYNVSEYMXME-LURJTMIESA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3
  • 重原子数:
    12
  • 可旋转键数:
    5
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.86
  • 拓扑面积:
    51.7
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2(S)-azido-3-ethylpentanoic acid 在 palladium 10% on activated carbon 、 氢气 作用下, 以 溶剂黄146 为溶剂, 反应 20.0h, 以79%的产率得到(S)-2-氨基-3-乙基戊酸
    参考文献:
    名称:
    Discovery of Begacestat, a Notch-1-Sparing γ-Secretase Inhibitor for the Treatment of Alzheimer’s Disease
    摘要:
    SAR on HTS hits I and 2 led to the potent, Notch-l-sparing GSI 9, which lowered brain A beta in Tg2576 mice at 100 mg/kg po. Converting the metabolically labile methyl groups in 9 to trifluoromethyl groups afforded the more stable analogue 10, which had improved in vivo potency. Further side chain modification afforded the potent Notch-1-sparing GSI begacestat (5). which was selected for development for the treatment of Alzheimer's disease.
    DOI:
    10.1021/jm801252w
  • 作为产物:
    描述:
    (2S),(4S)-3-(2-azido-3-ethyl-1-oxopentyl)-4-(phenylmethyl)-2-oxazolidinonelithium hydroxide monohydrate 作用下, 以 四氢呋喃 为溶剂, 以77%的产率得到2(S)-azido-3-ethylpentanoic acid
    参考文献:
    名称:
    Discovery of Begacestat, a Notch-1-Sparing γ-Secretase Inhibitor for the Treatment of Alzheimer’s Disease
    摘要:
    SAR on HTS hits I and 2 led to the potent, Notch-l-sparing GSI 9, which lowered brain A beta in Tg2576 mice at 100 mg/kg po. Converting the metabolically labile methyl groups in 9 to trifluoromethyl groups afforded the more stable analogue 10, which had improved in vivo potency. Further side chain modification afforded the potent Notch-1-sparing GSI begacestat (5). which was selected for development for the treatment of Alzheimer's disease.
    DOI:
    10.1021/jm801252w
点击查看最新优质反应信息

文献信息

  • Process for the synthesis of chirally pure beta-amino-alcohols
    申请人:Wyeth
    公开号:US20030144531A1
    公开(公告)日:2003-07-31
    A process is provided for preparing chirally pure S-enantiomers of &agr;-amino acids comprising the steps of: a) preparing an organometallic reagent from an alkyl halide of the formula (R) 2 CH(CH 2 ) n CH 2 X; b) adding the organometallic reagent to carbon dioxide to afford a carboxylic acid; c) activating the carboxylic acid with an acid chloride, phosphorus trichloride, acid anhydride, or thionyl chloride in the presence of a tertiary amine base; d) reacting the product of step c) with an alkali metal salt of S-4-benzyl-2-oxazolidinone; e) treating the product of step d) with a strong non-nucleophilic base to form an enolate anion; f) trapping the enolate anion with 2,4,6-triisopropylbenzenesulfonyl azide to afford an oxazolidinone azide; g) hydrolyzing the oxazolidinone azide with an aqueous base to afford an &agr;-azido acid; h) reducing the &agr;-azido acid to the &agr;-amino acid; and i) recrystallizing the &agr;-amino acid to the chirally pure &agr;-amino acid. A process is also provided for preparing chirally pure S-enantiomers of &bgr;-amino alcohols further comprising the steps of reducing the crude &agr;-amino acid to the &bgr;-amino alcohol and recrystallizing the &bgr;-amino alcohol to the chirally pure &bgr;-amino alcohol. A process is further provided for preparing chirally pure S enantiomers of N-sulfonyl &bgr;-amino alcohols further comprising the steps of sulfonylating the &bgr;-amino alcohol with 5-chloro-thiophene-2-sulfonyl halide; and recrystallizing to afford the chirally pure N-sulfonyl &bgr;-amino alcohols.
    提供了一种制备手性纯S-对映体α-氨基酸的过程,包括以下步骤:a) 从具有化学式(R)2CH(CH2)n X的烷基卤化物制备有机属试剂;b) 将有机属试剂加入二氧化碳以得到羧酸;c) 在三级胺碱存在下,用酸化物、三氯化磷、酸酐或氯化硫激活羧酸;d) 将步骤c)的产物与S-4-苄基-2-噁唑烷酮的碱属盐反应;e) 用强非亲核碱处理步骤d)的产物以形成烯醇负离子;f) 用2,4,6-三异丙基苯磺酰氮化物捕获烯醇负离子以得到噁唑烷酮氮化物;g) 用性碱噁唑烷酮氮化物以得到α-叠氮酸;h) 还原α-叠氮酸以得到α-氨基酸;i) 对α-氨基酸进行再结晶以得到手性纯α-氨基酸。还提供了一种制备手性纯S-对映体β-基醇的过程,进一步包括将粗α-氨基酸还原为β-基醇,并对β-基醇进行再结晶以得到手性纯β-基醇。还提供了一种制备手性纯S-对映体N-磺酰基β-基醇的过程,进一步包括用5-代苯磺酰卤化物对β-基醇进行磺酰化;并进行再结晶以得到手性纯N-磺酰基β-基醇。
  • PROCESS FOR THE SYNTHESIS OF CHIRALLY PURE b-AMINO-ALCOHOLS
    申请人:Wyeth
    公开号:EP1461303A2
    公开(公告)日:2004-09-29
  • US6800764B2
    申请人:——
    公开号:US6800764B2
    公开(公告)日:2004-10-05
  • [EN] PROCESS FOR THE SYNTHESIS OF CHIRALLY PURE beta -AMINO-ALCOHOLS<br/>[FR] PROCEDE DE SYNTHESE DE DOLLAR G(B)-AMINO-ALCOOLS A PURETE CHIRALE
    申请人:WYETH CORP
    公开号:WO2003050063A2
    公开(公告)日:2003-06-19
    A process is provided for preparing chirally pure S-enantiomers of α-amino acids comprising the steps of: a) preparing an organometallic reagent from an alkyl halide of the Formula (R)2CH(CH2)nCH2X; b) adding the organometallic reagent to carbon dioxide to afford a carboxylic acid; c) activating the carboxylic acid with an acid chloride, phosphorus trichloride, acid anhydride, or thionyl chloride in the presence of a tertiary amine base; d) reacting the product of step c) with an alkali metal salt of S-4-benzyl-2-oxazolidinone; e) treating the product of step d) with a strong non-nucleophilic base to form an enolate anion; f) trapping the enolate anion with 2,4,6-triisopropylbenzenesulfonyl azide to afford an oxazolidinone azide; g) hydrolyzing the oxazolidinone azide with an aqueous base to afford an α-azido acid; h) reducing the α-azido acid to the α-amino acid; and i) recrystallizing the α-amino acid to the chirally pure α-amino acid. A process is also provided for preparing chirally pure S-enantiomers of β-amino alcohols further comprising the steps of reducing the crude α-amino acid to the β-amino alcohol and recrystallizing the β-amino alcohol to the chirally pure β-amino alcohol. A process is further provided for preparing chirally pure S enantiomers of N-sulfonyl β-amino alcohols further comprising the steps of sulfonylating the β-amino alcohol with 5-chloro-thiophene-2-sulfonyl halide; and recrystallizing to afford the chirally pure N-sulfonyl β-amino alcohols.
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[[[(1R,2R)-2-[[[3,5-双(叔丁基)-2-羟基苯基]亚甲基]氨基]环己基]硫脲基]-N-苄基-N,3,3-三甲基丁酰胺 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,4R)-Boc-4-环己基-吡咯烷-2-羧酸 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-N,3,3-三甲基-N-(苯甲基)丁酰胺 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S)-2-氨基-3,3-二甲基-N-2-吡啶基丁酰胺 (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,5R,6R)-5-(1-乙基丙氧基)-7-氧杂双环[4.1.0]庚-3-烯-3-羧酸乙基酯 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素(1-6) 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸